About Us
Samsung Epis Holdings was established to apply fast-evolving biotechnology to pre-clinical and clinical assets and to manage the portfolio of biopharmaceutical products more effectively and swiftly in this rapidly-evolving biopharmaceutical industry.
The establishment of Samsung Epis Holdings has strengthened an independent decision-making structure, laying a foundation to advance as a top-tier global biopharmaceutical company.
and Shareholder Value
New Business Expansion
- Establishing biotechnology platforms
- Investing in new biopharma-related businesses
- M&A, venture investment
Subsidiary Business Management
- Identifying and securing global partnerships
- Delivering optimized strategies tailored to each company
- Enabling swift decision-making by experienced management
Profit Generation
- Management and support fees from subsidiaries
- Investment returns from new technologies
- Dividend income from subsidiaries
Samsung Epis Holdings will continue to embrace future challenges and drive ongoing innovation by developing tailored strategies for each subsidiary, building a global collaboration system, and identifying new growth drivers.
Samsung Bioepis aims to become the “world’s No. 1 biosimilar company” with more than 20 biosimilar assets in its products and pipeline. The patent expiration of biologic medicines and streamlined regulatory requirements for clinical comparative efficacy studies are expected to stimulate growth of the biosimilar market.
Epis NexLab will explore next-generation technologies for future growth. Building on the experience of developing Samsung Bioepis into a world-class biosimilar company, it will focus on developing various platform technologies, including peptides, dedicating itself to investing in future technologies and developing new businesses.
